affected by Multiple Sclerosis.
Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org
-- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Saturday, July 17, 2010
Staying on treatment
Managing MS symptoms
When to call someone about your symptoms
- If you experience loss of vision or blurry vision
- If you have an abrupt change in bowel or bladder function
- If you think you have a urinary tract infection
- If you have feelings of depression or thoughts of hurting yourself
- Any time you are concerned about a symptom or feeling
More on Symptom Management:
- Walking & Balance
- Bowel or Bladder
- Sexual Issues
- Beating The Heat
Source of these articles is MS Lifelines:
Friday, July 16, 2010
Thursday, July 15, 2010
The researchers found that the Callen MS-ADEM criteria had the best combination of sensitivity (75%) and specificity (95%). Although the KIDMUS criteria had a higher specificity (100%), they provided a much lower sensitivity (11%). The Barkhof criteria yielded a sensitivity of 61% and a specificity of 91%. Furthermore, the Callen diagnostic MS criteria were the most sensitive (82%), but they were 52% specific for distinguishing a first attack of MS from ADEM, according to the researchers.
The majority of surveyed physicians indicate that they will use the surveyed emerging oral agents in relapse/remitting MS patients who have failed therapy with interferon-betas and Teva's Copaxone. Only a small percentage (10 percent or less) will use the surveyed emerging oral agents in treatment-naive patients. Surveyed physicians report they will most likely prescribe these emerging oral agents for patients who cannot tolerate the side effects of their current therapy or who are unwilling to risk the side effects of Biogen Idec/Elan's Tysabri.
Makes me wonder how much general neurologists really know of the current ms therapies...
National MS Society Works with Reps. Kilroy & Thornberry to Introduce & Confirm Legislation to Cover Off-Label Prescriptions for Medicare Part D Carriers
Continue reading from here